LAVA Therapeutics (LVTX) Income Statement (2024 - 2025)
Income Statement report data from Mar 31, 2024 to Sep 30, 2025 for LAVA Therapeutics (LVTX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||
Total Revenue | - | - | - | 4.99M | - | - | 6.99M |
Operating Expenses | |||||||
Research And Development | 2.24M (-52.74%) | 4.74M (+13.94%) | 4.16M (-51.46%) | 8.57M (+3.50%) | 8.28M (+38.93%) | 5.96M (+5.49%) | 5.65M |
Selling General And Administrative | 5.31M (+108.24%) | 2.55M (-25.66%) | 3.43M (+2.39%) | 3.35M (+9.12%) | 3.07M (-10.76%) | 3.44M (+1.78%) | 3.38M |
Operating Expenses | 7.55M (+3.57%) | 7.29M (-3.95%) | 7.59M (-36.27%) | 12M (+5.03%) | 11M (+20.77%) | 9.39M (+3.99%) | 9.03M |
Depreciation And Amortization | - | - | 110K (-65.63%) | 320K | - | - | 140K |
Operating Income | |||||||
Operating Income | -7.55M (+3.57%) | -7.29M (-3.95%) | -7.59M (+9.68%) | -6.92M (-38.98%) | -11.34M (+20.77%) | -9.39M (+360.29%) | -2.04M |
Ebit | -7.55M (+3.57%) | -7.29M (-3.95%) | -7.59M (+9.68%) | -6.92M (-38.98%) | -11.34M (+20.77%) | -9.39M (+360.29%) | -2.04M |
EBITDA | -7.18M (-16.22%) | -8.57M (+14.57%) | -7.48M (+5.50%) | -7.09M (-41.55%) | -12.13M (+49.57%) | -8.11M (+329.10%) | -1.89M |
Other Income / Expenses | |||||||
Interest Income | 540K (-11.48%) | 610K (-14.08%) | 710K (-17.44%) | 860K (-10.42%) | 960K (-1.03%) | 970K (0.00%) | 970K |
Interest Expense | - | - | 100K (-41.18%) | 170K (+70.00%) | 100K (0.00%) | 100K (-23.08%) | 130K |
Net Interest Income | 540K (-11.48%) | 610K (-14.08%) | 710K (-17.44%) | 860K (-10.42%) | 960K (-1.03%) | 970K (0.00%) | 970K |
Other Non Operating Income | 370K | -1.28M | 4.33M (-16.89%) | 5.21M | -890.00K | 1.18M (-21.33%) | 1.50M |
Net Income | |||||||
Income Before Tax | -7.18M (-16.22%) | -8.57M (+163.69%) | -3.25M (-7.14%) | -3.50M (-71.38%) | -12.23M (+48.96%) | -8.21M (+1420.37%) | -540.00K |
Income Tax Expense | 10K (-85.71%) | 70K (-69.57%) | 230K (-39.47%) | 380K (+280.00%) | 100K (+11.11%) | 90K (+28.57%) | 70K |
Net Income From Continuing Operations | -7.19M (-16.78%) | -8.64M (+148.28%) | -3.48M (-10.31%) | -3.88M (-68.53%) | -12.33M (+48.55%) | -8.30M (+1260.66%) | -610.00K |
Net Income | -7.19M (-16.78%) | -8.64M (+148.28%) | -3.48M (-10.31%) | -3.88M (-68.53%) | -12.33M (+48.55%) | -8.30M (+1260.66%) | -610.00K |
Comprehensive Income Net Of Tax | -7.64M (+21.46%) | -6.29M (+151.60%) | -2.50M (-90.70%) | -26.87M (+153.49%) | -10.60M (+21.56%) | -8.72M (+428.48%) | -1.65M |